RQx Antibiotic Collaboration With Genentech Marks Third Exit For Avalon Ventures This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.